European Medicines Agency
Evaluation of Medicines for Human Use

London, 13th January 2009
EMEA/CHMP/679401/2008 – corr*

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE
DECEMBER 2008 PLENARY MEETING
MONTHLY REPORT

The Committee for Medicinal Products for Human Use (CHMP) held its December plenary meeting from 15-18 December 2008.

CENTRALISED PROCEDURE

Initial applications for marketing authorisation

The CHMP adopted six positive opinions by consensus on initial marketing authorisations.

New medicinal products

- **Efient** (prasugrel), from Eli Lilly and Company Limited, co-administered with acetylsalicylic acid, is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI). EMEA review began on 27 February 2008 with an active review time of 204 days;
- **Fablyn** (lasofoxifene), from Pfizer Ltd, for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. EMEA review began on 30 January 2008 with an active review time of 203 days;
- **Firmagon** (degarelix), from Ferring Pharmaceuticals A/S, for the treatment of advanced prostate cancer. EMEA review began on 26 March 2008 with an active review time of 195 days;
- **Intanza** (influenza vaccine, split virion inactivated), from Sanofi Pasteur MSD SNC, and **IDflu** (influenza vaccine, split virion inactivated), from Sanofi Pasteur S.A., for the prophylaxis of influenza. EMEA review began on 26 December 2007 with an active review time of 205 days;
- **Ixiaro** (Japanese encephalitis vaccine, inactivated, adsorbed), from Intercell AG, for the active immunisation against Japanese encephalitis in adults. Ixaro is the 52nd orphan medicine to receive a positive opinion from the CHMP. EMEA review began on 30 January 2008 with an active review time of 204 days;
- **Mepact** (mifamurtide), from IDM Pharma S.A., for the treatment of non-metastatic osteosarcoma. Mepact is the 53rd orphan medicine to receive a positive opinion from the CHMP. EMEA review began on 22 November 2006 with an active review time of 205 days.

Pandemic influenza vaccine

The CHMP adopted a positive opinion by consensus recommending the granting of a marketing authorisation under exceptional circumstances and subject to specific obligations that will be reviewed for the pandemic influenza vaccine **Celvapan** (pandemic influenza vaccine (H5N1 whole virion, vero cell derived, inactivated)), from Baxter AG. Pandemic vaccines are vaccines prepared from influenza viruses with a pandemic potential that are intended for use during an officially declared influenza pandemic. EMEA review began on 27 February 2008 with an active review time of 205 days.

* The information concerning the use of pandemic vaccine has been changed.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Further information on pandemic influenza vaccines can be found in a question-and-answer document here.

Summaries of opinion for these medicinal products are available on the EMEA website http://www.emea.europa.eu/htms/human/opinion/opinion.htm. Further information will be included in the European Public Assessment Report (EPAR) once the European Commission has granted final approval.

Re-examination procedure under Article 9(2) of Regulation (EC) No. 726/2004

The EMEA has been formally requested by Bristol-Myers Squibb EEIG to re-examine the negative opinion for **Ixempra** (ixapebilone) intended to be used for the treatment of metastatic or locally advanced breast cancer, adopted during the CHMP meeting on 17–20 November 2008.

Withdrawals

- The EMEA has been formally notified by Gendux Molecular Limited of its decision to withdraw its application for an initial marketing authorisation for **Advexin** (contusugene ladenovec). Advexin was expected to be used for the treatment of Li-Fraumeni cancer in patients from the age of 18 years as monotherapy. A separate press release with more information is available.
- The EMEA has been formally notified by Oncoscience AG of its decision to withdraw its application for an initial marketing authorisation for **Theraloc** (nimotuzumab), 5 mg/ml concentrate for solution for infusion. Theraloc was expected to be used to treat children and adolescents with resistant or recurrent high-grade glioma. Theraloc was designated as an orphan medicine on 2 September 2004. A separate press release and a question-and-answer document with more information are available.

Post-authorisation procedures

Extensions of indication and other recommendations

The CHMP gave two positive opinions by consensus for applications for extension of indication, adding new treatment options for the following previously approved medicines:

- **TachoSil** (human fibrinogen and human thrombin), from Nycomed Austria GmbH, to extend the indication to promote tissue sealing and for suture support in vascular surgery. TachoSil is currently indicated for supportive treatment in surgery for improvement of haemostasis where standard techniques are insufficient.
- **Zavesca** (miglustat), from Actelion Registration Ltd, to extend the indication to the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease. Zavesca is currently indicated for the oral treatment of mild to moderate type 1 Gaucher disease in patients for whom enzyme replacement therapy is unsuitable. Zavesca is an orphan-designated medicine.

Summaries of opinions for all mentioned products, including their full indication, can be found here.

Updated of product information recommended for anti-epileptic medicines

The CHMP recommended updating the product information of the centrally authorised antiepileptic medicines **Keppra** (levetiracetam), **Lyrica** (pregabalin), **Vimpat** (lacosamide) and **Zonegran** (zonisamide) with information on available evidence on the risk of suicidal thoughts and behaviour and advice to monitor patients for suicidal ideation or behaviour during treatment.

The CHMP recommendation follows a review by the Pharmacovigilance Working Party (PhVWP) of all antiepileptic medicines available in the European Union. Having reviewed the available evidence, the PhVWP concluded that the benefits of these medicines continue to outweigh their risks and that patients should continue to take antiepileptic medicines as prescribed. However, treatment with antiepileptic

medicines is associated with a small risk of suicidal thoughts and behaviour, and therefore the product information of all antiepileptic medicines in the EU should be updated with appropriate information.

Withdrawals

- The EMEA has been formally notified by Janssen-Cilag International N.V. of its decision to withdraw its application for an extension of indication for the treatment of acute manic episodes associated with bipolar I disorder for the centrally authorised medicine **Invega** (paliperidone) prolonged-release tablets. A separate press release with more information is available.
- The question-and-answer document on the withdrawal of application for **Viagra** (sildenafil) 50 mg film-coated tablets, which was originally announced in the November CHMP monthly report, is now available on the EMEA website.

OTHER INFORMATION ON THE CENTRALISED PROCEDURE

Lists of Questions

The Committee adopted nine Lists of Questions on initial applications (including two under the mandatory scope and seven under the optional scope).

Detailed information on the centralised procedure

An overview of centralised procedures since 1995 is given in **Annex 1**. The post-authorisation centralised procedures finalised during this meeting are summarised in **Annex 2**. The list of medicinal products for which marketing authorisations have been granted by the European Commission since the CHMP plenary meeting in November 2008 is provided in **Annex 3.**

Applications for marketing authorisation for orphan medicinal products

Details of those orphan medicinal products that have been subject of a centralised application for marketing authorisation since the November 2008 CHMP plenary meeting are provided in **Annex 4**.

REFERRAL PROCEDURES

Referral procedures concluded

The CHMP concluded a referral procedure under Article 29 of Directive 2001/83/EC, as amended. This type of procedures is initiated by one or more Member States in cases where an agreement cannot be reached in the context of the mutual recognition procedure or the decentralised procedure. The medicines concerned are:

- **Bleomycin Pharmachemie and associated names**, 15 U, powder for solution for injection (bleomycin), from Pharmachemie BV, used as an anti-cancer agent. The procedure was initiated due to disagreements regarding the safety of the medicine. The CHMP concluded that the benefits of the medicines outweigh its risks. Therefore, the CHMP recommended granting the marketing authorisations. A separate question-and-answer document with more information about the procedure is available here.
- **Sabumalin and associated names**, 100 µg/dose, suspension for pressurised inhalation (salbutamol), from Hexal AG, indicated for treatment of asthma or chronic obstructive pulmonary disease and to prevent asthma symptoms. The procedure was initiated due to disagreements regarding bioequivalence. The CHMP concluded that the medicine is bioequivalent to the reference product and that the benefits of the medicine outweigh its risks. Therefore, the CHMP recommended granting the marketing authorisations. A separate question-and-answer document with more information about the procedure is available here.

- **Sanohex and associated names**, 100 µg/dose, suspension for pressurised inhalation (salbutamol), from Hexal AG, indicated for treatment of asthma or chronic obstructive pulmonary disease and to prevent asthma symptoms. The procedure was initiated due to disagreements regarding bioequivalence. The CHMP concluded that the medicine is bioequivalent to the reference product and that the benefits of the medicine outweigh its risks. Therefore, the CHMP recommended granting the marketing authorisations. A separate question-and-answer document with more information about the procedure is available here.
- **Uman Big**, 180 IU/ml, solution for injection (human hepatitis B immunoglobulin), from Kedrion S.p.A., indicated for the immunoprophylaxis of hepatitis B in specific circumstances. The procedure was initiated due to disagreements regarding safety and efficacy. The CHMP concluded that the benefits of the medicine outweigh its risks. Therefore, the CHMP recommended granting the marketing authorisations. A separate question-and-answer document with more information about the procedure is available here.

The CHMP concluded a referral procedure under Article 30 of Directive 2001/83/EC as amended. This type of procedure is initiated with a view to harmonising product information for medicinal products authorised at Member State level. The CHMP recommended the amendment of the Summary of Product Characteristics, labelling and package leaflet for the following medicines:

- **Tritace and associated names** (ramipril), from Sanofi-Aventis group of companies and associated companies, indicated for the treatment of hypertension, cardiovascular disease prevention, myocardial infarction, renal disease and heart failure. A separate question-and-answer document with more information about the procedure is available here.
- **Tritazide and associated names** (ramipril and hydrochlorothiazide), from Sanofi-Aventis group of companies and associated companies, indicated for the treatment of hypertension. A separate question-and-answer document with more information about the procedure is available here.
- **Zoloft and associated names** (sertraline), from Pfizer group of companies and associated companies, indicated for the treatment of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder and post-traumatic stress disorder. A separate question-and-answer document with more information about the procedure is available here.

Referral procedures started

The CHMP started a referral procedure under Article 29 of Directive 2001/83/EC, as amended for **Ciclosporine IDL,** 25, 50 and 100 mg capsules (ciclosporin) from International Drug Licensing, used as an immunosuppressant drug. This type of procedure is initiated by one or more Member States in cases where an agreement cannot be reached in the context of the mutual recognition procedure or the decentralised procedure. In this particular case the procedure was initiated because of disagreements regarding bioequivalence.

The CHMP started a referral procedure under Article 30 of Directive 2001/83/EC as amended, for **Famvir and associated names** (famciclovir), from Novartis group of companies and associated companies, used as an antiviral drug.

MUTUAL RECOGNITION AND DECENTRALISED PROCEDURES - HUMAN

The CHMP noted the report from the 35th CMD(h) (Co-ordination Group for Mutual Recognition and Decentralised procedures-Human) held on 15-16 December 2008. For further details, please see the relevant press release on the CMD(h) website under the heading Press Releases: http://www.hma.eu/

CHMP WORKING PARTIES

The CHMP was informed of the outcome of the discussions of the Scientific Advice Working Party (SAWP) meeting, which was held 01-03 December 2008 For further details, please see **Annex 5**.

Documents prepared by the CHMP Working Parties adopted during the December 2008 CHMP meeting are listed in **Annex 6**.

UPCOMING MEETINGS FOLLOWING THE SEPTEMBER 2008 CHMP PLENARY MEETING

- The 51st meeting of the CHMP will be held at the EMEA on 19-22 January 2009.
- The next Name Review Group meeting will be held at the EMEA on 27 January 2009.
- The 36th CMD(h) (Co-ordination Group for Mutual Recognition and Decentralised Procedures) will be held at the EMEA on 19-20 January 2009.

ORGANISATIONAL MATTERS

The main topics addressed during the December 2008 CHMP meeting related to:

- The new Variation Regulation No 1234/2008. The Committee was informed that the new text has been published in the EU Official Journal. It will apply from 1 January 2010, with the exception of Art 5 (recommendations on unforeseen variations) which already has applied from 1 January 2009. Preparation for its implementation is ongoing.
- Further reflection on eligibility requests made under the optional scope Art (3)2b of Regulation 726/2004 (therapeutic, scientific, technical innovation or interest of patients at Community level). The Committee reviewed all cases received since the implementation of the new legislation (20 November 2005) with the prospect to further identify well defined criteria to be met by Applicants submitting eligibility requests under such indents of the optional scope.
- The presentation of an overview of the current EMEA procedure on the handling of conflicts of interest, reviewing the last 3 years of experience by the EMEA Declaration of Interest Assessment Group (DIAG). Further discussion will take place in early 2009.
- The imminent implementation of eCTD submissions in the centralised procedure from January 2009 onwards.
- The final adoption of the revision of the guidance on time allowed for applicants to respond to questions and issues raised during the assessment of new MAAs in the centralised procedure (EMEA/75401/2006 Rev. 2) following the public consultation that took place over 2008 summer. The final document, together with the overview of comments received, will be published on the EMEA website shortly.
- Preliminary discussion regarding the validation of statistical signal detection for centrally authorised medicinal products in EudraVigilance. The Committee was shown the results of a study evaluating the impact of using formal statistical signal detection methods to screen the EudraVigilance database for adverse drug reactions.
- The appointment of Dr. Margarida Menezes-Ferreira as the Portuguese alternate member for the Committee for Advanced Therapies.
- An update regarding the future Committee for Advanced Therapies activities that will start operating in January 2009.
- The EMEA-EFPIA information day that will be held on 24 February 2009. A preliminary draft agenda is available here.

Noël Wathion
Head of Unit
Post-Authorisation Evaluation of Medicines for Human Use, Tel. (+44-20) 74 18 85 92

This CHMP Monthly Report and other documents are available on the Internet at the following address:
http://www.emea.europa.eu

PRE-AUTHORISATION: MARKETING AUTHORISATION APPLICATIONS

Activity	2008								1995 onwards
	Optional Scope				Mandatory scope			Total	Overall total
	NAS	Significant innovation	Interest of Patients	Generics	Biotech	Indications	Orphans		
Applications for MA submitted	24	6	0	32	15	11	14	102	770
Positive opinions	23	5	0	4	13	12	7	64	493
Negative opinions[1]	0	0	0	0	0	1	2	3	21
Withdrawals prior to opinion	10	1	0	0	5	1	6	23	139
Marketing authorisation granted by the Commission	17	5	0	5	8	11	5	51	485

PRE-AUTHORISATION: SCIENTIFIC SERVICES

Activity (submissions)	2008	1995 onwards
Compassionate use applications	0	0
Art. 58 applications	0	4
Consultation for medical devices[2]	1	5
PMF (Click here for a list of PMF certifications)	2	13
VAMF	0	0

[1] In case of Re-examination under Art. 9(2) of Regulation (EC) No. 726/2004, the opinion will not be counted twice.
[2] Consultation in accordance with Council Directive 93/42/EEC concerning medical devices as amended by Directive 2000/70/EC as regards medical devices incorporating stable derivates of human blood or plasma and Directive 2001/104/EC

OUTCOME OF THE DECEMBER 2008 CHMP MEETING IN RELATION TO ACCELERATED ASSESMENT PROCEDURES

Substance	Intended indications(s)	Accelerated Assessment Requests	
		Accepted	Rejected
Chemical	N/A	N/A	N/A
Biological	N/A	N/A	N/A

ANNEX 2 TO CHMP MONTHLY REPORT DECEMBER 2008

POST-AUTHORISATION: TYPE I AND II VARIATIONS, ANNEX II, RENEWALS AND ANNUAL RE-ASSESSMENT APPLICATIONS

Activity	2008	Overall total 1995 onwards
Type I Variations (positive notifications)	1167	6369
Type II Variations (positive opinions)	699	4543
Type II Variations (negative opinions)	5	16
Annex II Applications (positive opinions)	32	201
Annual Re-assessment (positive opinions)	24	-
Opinion for renewals of conditional MA's (positive opinions)	4	6
5 Year Renewals (positive opinions)	48	-

Opinions for Type II Variation applications	
Number of Opinions	**Outcome**
2 Extension of indication	2 Positive opinions
41 SPC changes	41 Positive opinions
29 Quality changes	29 Positive opinions

Opinions for Annual Re-Assessment applications		
Name of Medicinal Product (INN) MAH	**Outcome**	**Comments**
Benefix (nonacog alfa) Wyeth Europe Ltd	Positive Opinion adopted	The marketing authorisation remains under exceptional circumstances.
Evoltra (clofarabine) Bioenvision Limited	Positive Opinion adopted	The marketing authorisation remains under exceptional circumstances.
Replagal (agalsidase alfa) TKT Europe-5S AB	Positive Opinion adopted	The marketing authorisation remains under exceptional circumstances.

Opinion for renewals of conditional MA's		
Name of Medicinal Product (INN) **MAH**	**Outcome**	**Comments**
Vectibix (Panitumumab) Amgen Europe B.V	Positive Opinion adopted	N/A

Opinions for 5-Year Renewal applications		
Name of Medicinal Product (INN) **MAH**	**Outcome**	**Comments**
PhotoBarr (porfimer sodium) Axcan Pharma International BV	Positive Opinion adopted	Recommending additional renewal
Advate (octocog alfa) Baxter AG	Positive Opinion adopted	Recommending additional renewal
Bondenza (ibandronic acid) Roche Registration Ltd	Positive Opinion adopted	Recommending additional renewal
Bonviva (ibandronic acid) Roche Registration Ltd	Positive Opinion adopted	Recommending additional renewal
Sonata (zaleplon) Meda AB	Positive Opinion adopted	Unlimited validity
Zerene (zaleplon) Meda AB	Positive Opinion adopted	Unlimited validity

ANNEX 3 TO CHMP MONTHLY REPORT DECEMBER 2008

MEDICINAL PRODUCTS GRANTED A COMMUNITY MARKETING AUTHORISATION UNDER THE CENTRALISED PROCEDURE SINCE THE NOVMEBER 2008 CHMP MONTHLY REPORT

Invented Name	ZYPADHERA
INN	olanzapine
Marketing Authorisation Holder	Eli Lilly Nederland B.V
Proposed ATC code	N05A H03
Indication	Maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine.
CHMP Opinion date	25.09.2008
Marketing Authorisation Date	19.11.2008

Invented Name	Kuvan
INN	sapropterin dihydrochloride
Marketing Authorisation Holder	Merck KGaA
Proposed ATC code	A16AX07
Indication	Kuvan is indicated for the treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients of 4 years of age and over with phenylketonuria (PKU) who have been shown to be responsive to such treatment. Kuvan is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment.
CHMP Opinion date	25.09.2008
Marketing Authorisation Date	02.12.2008

Invented Name	AZARGA
INN	brinzolamide/timolol
Marketing Authorisation Holder	Alcon Laboratories (UK) Ltd
Proposed ATC code	S01ED51
Indication	Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.
CHMP Opinion date	25.09.2008
Marketing Authorisation Date	25.11.2008

Invented Name	Irbesartan Krka
INN	Irbesartan
Marketing Authorisation Holder	Krka, d.d., Novo mesto
Proposed ATC code	C09CA04
Indication	Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.
CHMP Opinion date	25.09.2008
Marketing Authorisation Date	01.12.2008

Invented Name	Jalra
INN	vildagliptin
Marketing Authorisation Holder	Novartis Europharm Ltd
Proposed ATC code	A10BH02
Indication	Vildagliptin is indicated in the treatment of type 2 diabetes mellitus: As dual oral therapy in combination with metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin, a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance, a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate.
CHMP Opinion date	25.09.2008
Marketing Authorisation Date	19.11.2008

Invented Name	Xiliarx
INN	vildagliptin
Marketing Authorisation Holder	Novartis Europharm Ltd
Proposed ATC code	A10BH02
Indication	Vildagliptin is indicated in the treatment of type 2 diabetes mellitus: As dual oral therapy in combination with metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin, a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate

	due to contraindications or intolerance, a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate.
CHMP Opinion date	25.09.2008
Marketing Authorisation Date	19.11.2008

Invented Name	Zomarist
INN	vildagliptin / metformin hydrochloride
Marketing Authorisation Holder	Novartis Europharm Ltd.
Proposed ATC code	A10BD08
Indication	Zomarist is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
CHMP Opinion date	25.09.2008
Marketing Authorisation Date	01.12.2008

Invented Name	Vildagliptin/metformin hydrochloride Novartis
INN	vildagliptin / metformin hydrochloride
Marketing Authorisation Holder	Novartis Europharm Ltd.
Proposed ATC code	A10BD08
Indication	Zomarist is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets
CHMP Opinion date	25.09.2008
Marketing Authorisation Date	01.12.2008

ANNEX 4 TO CHMP MONTHLY REPORT DECEMBER 2008

OVERVIEW OF DESIGNATED ORPHAN MEDICINAL PRODUCTS THAT HAVE BEEN THE SUBJECT OF A CENTRALISED APPLICATION FOR MARKETING AUTHORISATION:
UPDATE SINCE THE NOVEMBER 2008 CHMP MEETING

Active substance	**Sponsor/applicant**	**EU Designation Number & Date of Orphan Designation**	**Designated Orphan Indication**
Adenovirus mediated *Herpes simplex* virus thymidine kinase (HKSV-tk) gene	Ark Therapeutics Ltd	EU/3/01/083	Treatment of high grade glioma with subsequent use of ganciclovir sodium

ANNEX 5 TO CHMP MONTHLY REPORT DECEMBER 2008

PRE-AUTHORISATION: SCIENTIFIC ADVICE AND PROTOCOL ASSISTANCE
EMEA CENTRALISED PROCEDURES

	1995 - 2007	2008	Overall Total
Scientific Advice	887	208	1095
Follow-up to Scientific Advice	171	56	227
Protocol Assistance	198	45	243
Follow-up to Protocol Assistance	90	20	110
	1346	**329**	**1675**

Final Scientific Advice Procedures

Substance	Intended indications(s)	Type of Request				Topic			
		New		Follow-up		Pharmaceutical	Pre-clinical	Clinical	Significant Benefit
		SA	PA	SA	PA				
Chemical	Treatment of gastroesophageal reflux disease			X				X	
Biological	Treatment of diabetes mellitus			X				X	
Biological	Treatment of diabetes mellitus	X						X	
Chemical	Treatment of Type 2 diabetes			X				X	
Chemical	Treatment of obesity	X					X	X	
Biological	Treatment of metachromatic leukodystrophy				X		X	X	
Biological	Treatment of neutropenias			X		X		X	
Biological	Treatment of arthritis	X						X	
Chemical	Treatment of non-small cell lung cancer			X			X	X	

Substance	Intended indications(s)	Type of Request				Topic			
		New		Follow-up		Pharmaceutical	Pre-clinical	Clinical	Significant Benefit
		SA	PA	SA	PA				
Chemical	Treatment of diffuse large B-Cell lymphoma	X						X	
Chemical	Treatment of chronic idiopathic myelofibrosis			X		X		X	
Biological	Treatment of inflammatory arthritis	X						X	
Biological	Treatment of idiopathic thrombocytopenic purpura		X			X			
Biological	Treatment of breast cancer	X				X	X		
Biological	Prophylaxis of venous thromboembolic events	X				X			
Biological	Treatment of acute myocardial infarction			X				X	
Biological	Treatment of neuropathic diabetic foot ulcers	X				X		X	
Biological	Treatment of eschar in deep partial thickness and full thickness burns				X			X	
Chemical	Treatment of mycoses	X				X	X	X	
Chemical	Treatment of hepatitis C	X					X	X	
Chemical	Treatment of HIV-1 infection			X		X		X	
Biological	Prevention of N. meningococcal serogroup B disease			X		X		X	

Substance	Intended indications(s)	Type of Request				Topic			
		New		Follow-up		Pharmaceutical	Pre-clinical	Clinical	Significant Benefit
		SA	PA	SA	PA				
Biological	Immunization against enterotoxigenic Escherichia coli disease	X				X		X	
Biological	Pandemic influenza vaccine	X					X	X	
Chemical	Contraceptive	X				X	X	X	
Biological	Treatment of lower urinary tract symptoms due to benign prostatic hyperplasia	X					X	X	
Biological	Removal of animal derived materials from manufacturing process	X				X	X		
Biological	Treatment of Alzheimer's disease			X				X	
Chemical	Sedation before and during diagnostic and therapeutic procedure	X				X	X	X	
Chemical	Treatment of Alzheimer's disease	X					X	X	
Chemical	Treatment of acute migraine with or without aura			X			X	X	
Chemical	Treatment of pulmonary arterial hypertension		X			X	X	X	X
Chemical	Treatment of asthma and COPD	X				X		X	
Chemical	Treatment of Cushing’s disease	X						X	
Biological	Treatment of post-menopausal osteoporosis	X					X	X	
Chemical	Treatment of hyperphos-phataema in end stage renal disease			X		X	X	X	

SA: Scientific Advice
PA: Protocol Assistance

The above-mentioned 20 Scientific Advice letters, 2 Protocol Assistance letters, 12 Follow-up Scientific Advice and 2 Follow-up Protocol Assistance letters were adopted at the 15-18 December 2008 CHMP meeting.

New requests for Scientific Advice Procedures

The Committee accepted 21 new Requests for which the procedure started at the SAWP meeting held on 01-03 December 2008. The new requests are divided as follows: 15 Initial Scientific Advice, 3 Follow-up Scientific Advice and 3 Initial Protocol Assistance.

ANNEX 6 TO CHMP MONTHLY REPORT DECEMBER 2008

DOCUMENTS PREPARED BY THE CHMP WORKING PARTIES ADOPTED DURING THE DECEMBER 2008 CHMP MEETING

BIOLOGICS WORKING PARTY (BWP)

Reference number	Document	Status[3]
CHMP/BWP/157653/2007 EMEA/CHMP/BWP/ 651330/2008	Guideline on the "Development, production, characterisation and specifications for monoclonal antibodies and related products" Overview of comments received	Adopted
EMEA/CPMP/VEG/4717/ 03- Rev.1	Revision of the Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisation Applications	Adopted

VACCINE WORKING PARTY (VWP)

Reference number	Document	Status[3]
EMEA/CHMP/VWP/ 614973/2008	Draft Guideline on Dossier Structure and Content of Pandemic Influenza Marketing Authorisations	Adopted

QUALITY WORKING PARTY (QWP)

Reference number	Document	Status[3]
EMEA/CHMP/CVMP/ QWP/662979/2008	Answers to CMD(h) questions on the need for in vitro dissolution studies with alcohol for all modified-release oral opioid products	Adopted
EMEA/CHMP/CVMP/ QWP/663057/2008	QWP position on CMD(h) problem statement regarding statistical methods to assess similarity in dissolution studies	Adopted
EMEA/CHMP/CVMP/ QWP/663093/2008	Question and Answer document on Plastic immediate packaging material	Adopted subject to final adoption by CVMP

EFFICACY WORKING PARTY (EWP)

Reference number	Document	Status[3]
EMEA/CHMP/EWP/ 356954/2008	CHMP Guideline on the Clinical Investigations of Medicinal Products for the Treatment of Pulmonary Arterial Hypertension	Adopted for 6-month public consultation
EMEA/CHMP/EWP/ 431734/2008	Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)	Adopted for 6-month public consultation
CHMP/EWP/369963/2005	Guideline on the development of medicinal products for the	Adopted

[3] Adopted or release for consultation documents can be found at the EMEA website (under "What's new-recent publications" or under Human Medicines-Guidance documents").

Reference number	Document	Status[3]
	treatment of smoking	
EMEA/CHMP/EWP/ 531305/2008	Concept Paper /recommendation on the need for a (CHMP) Guideline on the Validation of Bioanalytical Methods	Adopted for 3-month public consultation
EMEA/CHMP/EWP/ 545456/2008	Concept Paper on the Need of a Paediatric Addendum on the Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Hypertension	Adopted for 3-month public consultation
EMEA/618604/2008	EWP-PK subgroup Position Papers on specific questions	The document will be publish in January/February 2009 at http://www.emea.europa.eu/htms/human/humanguidelines/efficacy.htm